Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

1(50.0%)

Phase 4

1(50.0%)

2Total

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02440126Completed

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

Role: lead

NCT02965170Completed

Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS

Role: lead

NCT01569451Phase 2Completed

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Role: collaborator

NCT02217982Phase 4Terminated

Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

Role: lead

NCT01945359Completed

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

Role: lead

All 5 trials loaded